Intel R&D increased by 4.8% to $3.38B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 7.3%, from $3.64B to $3.38B. Over 4 years (FY 2021 to FY 2025), R&D shows relatively stable performance with a -2.4% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.72B | $3.80B | $4.05B | $4.36B | $4.40B | $4.30B | $4.46B | $4.11B | $4.08B | $3.87B | $3.99B | $4.38B | $4.24B | $4.05B | $3.88B | $3.64B | $3.68B | $3.23B | $3.22B | $3.38B |
| QoQ Change | — | +2.4% | +6.5% | +7.7% | +0.9% | -2.2% | +3.8% | -8.0% | -0.7% | -5.1% | +3.0% | +9.9% | -3.3% | -4.5% | -4.3% | -6.1% | +1.2% | -12.3% | -0.4% | +4.8% |
| YoY Change | — | — | — | — | +18.4% | +13.1% | +10.2% | -5.8% | -7.3% | -10.0% | -10.7% | +6.6% | +3.9% | +4.6% | -2.8% | -16.9% | -13.1% | -20.2% | -17.0% | -7.3% |